Afatinib is an irreversible inhibitor of the ErbB family of tyrosine kinases, which is the first‐line treatment for patients with advanced NSCLC as well as patients with brain metastases and activating EGFR mutations [42], including common mutations (Exon19Del/L858R) and uncommon mutations (S768I/G719X/L861Q) [43]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.